NIH: Hi Dose Calcifediol/Vitamin D Treatment In Covid Patients Cut ICU Admission, Pilot Study Spain
Last edited Wed Sep 9, 2020, 01:52 AM - Edit history (1)
NIH, NCBI, "Effect of Calcifediol Treatment & best Available Therapy versus best Available Therapy on Intensive Care Unit Admission & Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study." Aug. 29, 2020.
ABSTRACT, OBJECTIVE: The vitamin D endocrine system may have a variety of actions on cells & tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly increase serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19. DESIGN: parallel pilot randomized open label, double-masked clinical trial. SETTING: university hospital setting (Reina Sofia University Hospital, Córdoba Spain.)
PARTICIPANTS: 76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia & by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1). PROCEDURES: All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400?mg every 12?hrs on the first day, & 200?mg every 12?hrs for the following 5 days), azithromycin (500?mg orally for 5 days...Patients in the calcifediol treatment group continued with oral calcifediol (0.266?mg) on day 3 & 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission & deaths.
RESULTS: Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50%) p value X2 Fischer test p?<?0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95%CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension & T2DM): 0.03 (95%CI: 0.003-0.25). **Of the patients treated with calcifediol, none died, & all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died & the remaining 11 were discharged.
CONCLUSION: Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer...
More, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456194/
______________
- Vitamin D, First Clinical Trial. Dr. John Campbell.
Also: 'New Covid Pilot Study In Spain Shows Vit. D Treatment Cut ICU Admissions From 50% To 2%,' Daily Kos, 9/6/20.
https://democraticunderground.com/1016268326
..It is important to note that Vitamin D is not recommended as a treatment for COVID-19 but that deficiency will compromise the body’s immune system. However Dr John Campbell today posted a video reporting on a small trial study conducted in the Reina Sofia University Hospital, Córdoba Spain. This identified 76 patients at random who were positive for SARS-CoV-2 and who were shown to have viral pneumonia based on radiographic results (ie X-rays or scans).
All were treated according to the protocol used in the hospital at the time which included administering “a combination of hydroxychloroquine (400 mg every 12 hours on the first day, and 200 mg every 12 hours for the following 5 days), azithromycin (500 mg orally for 5 days.” While the use of Trump’s “hydroxy” has been discontinued in most circumstances, it is important to note that the only difference in treatment between the groups was that one received a drug called calcifediol. This is a commonly used drug taken to treat severe Vitamin D deficiency. While the body takes around 7 days to “process” vitamin D from food or tablets into the active form, this is an intermediate produced by the liver then further processed by the kidneys.
Calcifediol, also known as calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D (abbreviated 25(OH)D) is a prehormone that is produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme cholecalciferol 25-hydroxylase. Physicians worldwide measure this metabolite to determine a patient's vitamin D status.[2][3] At a typical daily intake of vitamin D3, its full conversion to calcifediol takes approximately 7 days.[4] Calcifediol is then converted in the kidneys (by the enzyme 25(OH)D-1?-hydroxylase) into calcitriol (1,25-(OH)2D3), a secosteroid hormone that is the active form of vitamin D. Dr Campbell notes that going out in the sun is not a cultural norm in that area of Spain so a degree of vitamin D deficiency is likely.
The results from this small but well conducted trial are remarkable... - More at the Link above.
= new reply since forum marked as read
